Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 3/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 5/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.38 |
| ▸ | CDC42 | P60953 | 1/20 | 0.38 |
| ▸ | RAC1 | P63000 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25072232 | 0.78 | HTR6 (0.62) | MTNR1AAKR1C3AKR1C2HTR6 | |
| SCHEMBL25072193 | 0.73 | HTR1A (0.46) | MTNR1AAKR1C3AKR1C2EPHX2HTR6 | |
| SCHEMBL25072233 | 0.72 | HTR6 (0.60) | MTNR1AAKR1C3AKR1C2EPHX2HTR6 | |
| SCHEMBL2686293 | 0.72 | MTNR1A (0.64) | MTNR1AMTNR1BAKR1C3AKR1C2PTGS2 | |
| SCHEMBL456876 | 0.71 | AKR1C3 (0.60) | AKR1C3AKR1C2PTGS2PTGS1CYP1A2 | |
| SCHEMBL469567 | 0.71 | AKR1C3 (0.60) | AKR1C3AKR1C2PTGS2PTGS1CYP1A2 | |
| SCHEMBL456875 | 0.71 | AKR1C3 (0.60) | AKR1C3AKR1C2PTGS2PTGS1CYP1A2 | |
| SCHEMBL25072182 | 0.71 | HTR6 (0.58) | MTNR1AEPHX2HTR6 | |
| SCHEMBL11569102 | 0.71 | AKR1C3 (0.65) | AKR1C3AKR1C2PTGS2PTGS1CYP1A2 | |
| SCHEMBL2005467 | 0.68 | PTGS2 (0.46) | MTNR1AMTNR1BAKR1C3AKR1C2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160120995-A1 | CONJUGATES OF POLYUNSATURATED FATTY ACIDS AND AMINE-CONTAINING COMPOUNDS AND USES THEREOF | MEDWELL LAB LTD (IL) | 2016-05-05 | — | — | US | disclosed |
| EP-2613779-A2 | CONJUGATES OF POLYUNSATURATED FATTY ACIDS AND AMINE-CONTAINING COMPOUNDS AND USES THEREOF | Medwell Laboratories Ltd. (IL) | 2013-07-17 | — | — | EP | disclosed |
| US-20130158070-A1 | CONJUGATES OF POLYUNSATURATED FATTY ACIDS AND AMINE-CONTAINING COMPOUNDS AND USES THEREOF | MEDWELL LABORATORIES LTD. (IL) | 2013-06-20 | — | — | US | disclosed |
| WO-2012032509-A2 | CONJUGATES OF POLYUNSATURATED FATTY ACIDS AND AMINE-CONTAINING COMPOUNDS AND USES THEREOF | MEDWELL LABORATORIES LTD. (IL) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158070-A1 | CONJUGATES OF POLYUNSATURATED FATTY ACIDS AND AMINE-CONTAINING COMPOUNDS AND USES THEREOF | ALOX5, ALOX15B, ALOX15 | MTNR1A 254/4885MTNR1B 243/4885AKR1C3 888/4885 |
| US-20160120995-A1 | CONJUGATES OF POLYUNSATURATED FATTY ACIDS AND AMINE-CONTAINING COMPOUNDS AND USES THEREOF | ALOX5, ALOX15B, ALOX15 | MTNR1A 250/4885MTNR1B 247/4885AKR1C3 918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.